Literature DB >> 30522958

The movement disorder spectrum of SCA21 (ATX-TMEM240): 3 novel families and systematic review of the literature.

Andreas Traschütz1, Judith van Gaalen2, Mayke Oosterloo3, Maaike Vreeburg4, Erik-Jan Kamsteeg5, Natalie Deininger6, Olaf Rieß6, Matthias Reimold7, Tobias Haack6, Ludger Schöls1, Bart P van de Warrenburg2, Matthis Synofzik8.   

Abstract

Spinocerebellar ataxia type 21 (SCA21/ATX-TMEM240) was recently found to be caused by mutations in TMEM240, with still limited knowledge on the phenotypic spectrum and disease course. Here we present five subjects from three novel SCA21 families from different parts of the world (including a novel c.196G > A, p.G66R TMEM240 variant from Colombia), demonstrating that, in addition to cerebellar ataxia, not only hypokinetic features (hypomimia, bradykinesia), but also hyperkinetic movement disorders (poly-mini-myoclonus, proximal myoclonus) are a recurrent part of the phenotypic spectrum of SCA21. Presenting first prospective longitudinal data, our results provide examples of two different disease trajectories: while it was inherently progressive in adult-onset cases, a dramatically improving trajectory was observed in an infantile-onset case. A systematic review of all previously reported SCA21 patients (n = 42) demonstrates that SCA21 is a relatively early-onset SCA (median onset age 18 years; range 1-61 years) with frequent non-cerebellar involvement, including hyporeflexia (69%), bradykinesia (65%), slow saccades (38%) and pyramidal signs (17%). Our results characterize SCA21 as a multisystem disorder with substantial extra-cerebellar involvement, including a wide spectrum of hypo- as well as hyperkinetic movement disorders as well as damage to the midbrain, corticospinal tract and peripheral nerves. However, in contrast to the current perspective on SCA21 disease, cognitive impairment is not an obligatory feature of the disease. The disease course is inherently progressive in adult-onset subjects, but might also be characterized by improvement in infantile-onset cases. These findings have important consequences of the work-up and counseling of SCA21/ATX-TMEM240 patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ataxia; Bradykinesia; Genetics; Hyperkinetic; Myoclonus; Parkinsonism; Spinocerebellar ataxia; Spinocerebellar ataxia type 21; TMEM240

Mesh:

Year:  2018        PMID: 30522958     DOI: 10.1016/j.parkreldis.2018.11.027

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

1.  The Neurodevelopmental and Motor Phenotype of SCA21 (ATX-TMEM240).

Authors:  Emma D Burdekin; Brent L Fogel; Shafali S Jeste; Julian Martinez; Jessica E Rexach; Charlotte DiStefano; Carly Hyde; Tabitha Safari; Rujuta B Wilson
Journal:  J Child Neurol       Date:  2020-07-24       Impact factor: 1.987

2.  The First Korean Family of Spinocerebellar Ataxia 21 (ATX-TMEM240) with Facial Dystonic Phenotype.

Authors:  Don Gueu Park; Min Seung Kim; Jung Han Yoon
Journal:  Cerebellum       Date:  2022-01-10       Impact factor: 3.847

3.  On Spinocerebellar Ataxia 21 as a Mimicker of Cerebral Palsy.

Authors:  Johanna van der Put; Dalia Daugeliene; Åsa Bergendal; Malin Kvarnung; Per Svenningsson; Martin Paucar
Journal:  Neurol Genet       Date:  2022-05-31

4.  Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer.

Authors:  Ruo-Kai Lin; Chih-Ming Su; Shih-Yun Lin; Le Thi Anh Thu; Phui-Ly Liew; Jian-Yu Chen; Huey-En Tzeng; Yun-Ru Liu; Tzu-Hao Chang; Cheng-Yang Lee; Chin-Sheng Hung
Journal:  Mol Med       Date:  2022-06-17       Impact factor: 6.376

Review 5.  The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Review.

Authors:  Hélio A G Teive; Alex T Meira; Carlos Henrique F Camargo; Renato P Munhoz
Journal:  Mov Disord Clin Pract       Date:  2019-08-16

6.  Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction.

Authors:  Shih-Ching Chang; Phui-Ly Liew; Muhamad Ansar; Shih-Yun Lin; Sheng-Chao Wang; Chin-Sheng Hung; Jian-Yu Chen; Shikha Jain; Ruo-Kai Lin
Journal:  Clin Epigenetics       Date:  2020-05-12       Impact factor: 6.551

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.